Does the Benefit of Thrombectomy in Large Strokes Depend on Perfusion-Diffusion Mismatch? A Large Stroke Therapy Evaluation Trial Post Hoc Analysis
Por:
Ter Schiphorst, A, Arquizan, C, Turc, G, Labreuche, J, Lapergue, B, Liebeskind, DS, Henon, H, Nouri, N, Albucher, JF, Cognard, C, Marnat, G, Sibon, I, Gory, B, Richard, S, Naggara, O, Annan, M, Boulouis, G, Omer, EF, Cho, TH, Di Maria, F, Bourcier, R, Guillon, B, Obadia, M, Piotin, M, Ferrier, A, Chabert, E, Millán, M, van Dokkum, L, Jovin, TG, Le Bars, E and Costalat, V
Publicada:
1 ene 2026
Resumen:
Background and Purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large Stroke Therapy Evaluation (LASTE) randomized controlled trial (RCT). Methods The LASTE RCT compared MT plus best medical treatment (BMT) to BMT alone in patients with large infarct (Alberta Stroke Program Early CT Score 0-5) in the 0-7-hour time-window. This secondary analysis was restricted to patients with available baseline MR perfusion-weighted imaging. We investigated the potential heterogeneity of MT treatment according to the presence of perfusion-diffusion mismatch, defined as a mismatch ratio >= 1.2, calculated as the time-to-maximum >6 seconds cerebral volume divided by ischemic core volume. The primary outcome was better functional outcome (favorable shift in the distribution of modified Rankin Scale [mRS] at 90 days, analyzed using generalized odds ratio [GenOR]). Results A total of 102/324 patients were included, among whom 55 (54%) had a perfusion-diffusion mismatch. No significant treatment effect heterogeneity by diffusion-perfusion mismatch was observed for the primary outcome (GenOR for better functional outcome: 1.70 [95% confidence interval, CI, 0.95 to 3.05] and 1.04 [95% CI, 0.57 to 1.87] in patients with and without mismatch, respectively; ratio of GenORs: 1.63 [95% CI, 0.71 to 3.74]; P for heterogeneity=0.24) or for the secondary efficacy and safety outcomes. Conclusions Our study found no evidence of heterogeneity of treatment effect with respect to benefit or safety in patients with unrestricted infarct size at baseline treated with MT by presence of perfusion-diffusion mismatch. An individual participant-data meta-analysis of RCT is needed for definitive conclusions.
Filiaciones:
Ter Schiphorst, A:
CHRU Gui de Chauliac, Dept Neurol, Montpellier, France
Univ Montpellier, Inst Genom Fonct, CNRS, INSERM, Montpellier, France
Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France
Arquizan, C:
CHRU Gui de Chauliac, Dept Neurol, Montpellier, France
Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France
Turc, G:
Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France
Hop St Anne, Dept Neurol, GHU Paris Psychiat & Neurosci, Paris, France
Labreuche, J:
Ctr Hosp Univ CHU Lille, Dept Biostat, Lille, France
Lapergue, B:
Versailles St Quentin En Yvelines Univ, Foch Hosp, Dept Neurol, Suresnes, France
Liebeskind, DS:
Univ Calif Los Angeles, UCLA Comprehens Stroke Ctr, Dept Neurol, Los Angeles, CA USA
Henon, H:
Ctr Hosp Univ CHU Lille, Dept Neurol, Lille, France
Nouri, N:
Ctr Hosp Univ CHU Lille, Dept Neuroradiol, Lille, France
Albucher, JF:
Hop Pierre Paul Riquet, Dept Neurol, Toulouse, France
Toulouse Clin Invest Ctr 1436, Toulouse, France
Cognard, C:
Toulouse Clin Invest Ctr 1436, Toulouse, France
Hop Pierre Paul Riquet, Dept Neuroradiol, Toulouse, France
Marnat, G:
Hop Pellegrin, Dept Neuroradiol, Bordeaux, France
Sibon, I:
Hop Pellegrin, Dept Neurol, Bordeaux, France
Gory, B:
Univ Lorraine, Dept Diagnost & Therapeut Neuroradiol, CHRU Nancy, Nancy, France
Univ Lorraine, CHRU Nancy, INSERM, CIC,U1254,Innovat Technol, Nancy, France
Richard, S:
Hop Cent, Dept Neurol, Nancy, France
INSERM, Ctr Invest Clin Plurithemat 1433, Nancy, France
Naggara, O:
Univ Paris Cite, Inst Psychiat & Neurosci Paris, INSERM, U1266, Paris, France
Hop St Anne, Dept Neuroradiol, GHU Paris Psychiat & Neurosci, Paris, France
Annan, M:
Hop Bretonneau, Dept Neurol, Tours, France
Boulouis, G:
Hop Bretonneau, Dept Neuroradiol, Tours, France
Omer, EF:
Hop Pierre Wertheimer, Dept Neuroradiol, Hosp Civils Lyon, Grp Hosp Est, Lyon, France
Cho, TH:
Hop Pierre Wertheimer, Dept Neurol, Hosp Civils Lyon, Grp Hosp Est, Lyon, France
Di Maria, F:
Versailles St Quentin En Yvelines Univ, Foch Hosp, Dept Neuroradiol, Suresnes, France
Bourcier, R:
Nantes Univ, Dept Neuroradiol, CHU Nantes, Nantes, France
Univ Nantes, Inst Thorax, Ctr Natl Rech Sci, INSERM Un Mixte Rech 1087, Nantes, France
Guillon, B:
CHU Nantes, Dept Neurol, Hop GR Laennec, Nantes, France
Obadia, M:
Hop Fdn Adolphe de Rothschild, Dept Neurol, Paris, France
Piotin, M:
Hop Fdn Adolphe de Rothschild, Dept Interventionnal Neuroradiol, Paris, France
Ferrier, A:
CHU Clermont Ferrand, Hop Gabriel Montpied, Dept Neurol, Clermont Ferrand, France
Chabert, E:
CHU Clermont Ferrand, Hop Gabriel Montpied, Dept Neuroradiol, Clermont Ferrand, France
:
Hosp Germans Trias i Pujol, Dept Neurol, Badalona, Spain
Jovin, TG:
Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Neurol, Camden, NJ USA
Le Bars, E:
CHRU Gui de Chauliac, Dept Neuroradiol, Montpellier, France
Univ Montpellier, CNRS, L2C, Montpellier, France
Costalat, V:
Univ Montpellier, Inst Genom Fonct, CNRS, INSERM, Montpellier, France
CHRU Gui de Chauliac, Dept Neuroradiol, Montpellier, France
Green Submitted, gold
|